Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Skin Organoid Patent Registration
04
2025.02
On February 4th, Kangstem Biotech announced the registration of a patent for a technology related to creating atopic dermatitis models based on skin organoids.
On February 4th, Kangstem Biotech announced the registration of a patent for a technology related to creating atopic dermatitis models based on skin organoids. The patent, resulting from a collaborative study with Professor Kang Kyung-sun’s research team at Seoul National University’s College of Veterinary Medicine, concerns the technology for generating flat skin organoids derived from pluripotent stem cells and the method for using them to create atopic dermatitis models.
The skin organoid developed by Kangstem Biotech is produced in a flat shape, similar to actual skin, and implements detailed skin layers(such as the stratum corneum and granular layer) that were previously unobservable in conventional organoids. The most notable feature of this technology is that, unlike spherical organoids, it can simulate various routes for applying substances to the skin, such as transdermal(epidermal layer) and intravenous administration, enabling the screening of various active substances. Moreover, the technology successfully replicates an atopic dermatitis model in the skin organoid, allowing for the evaluation of the efficacy of candidate substances.
The R&D director of Kangstem Biotech stated, "Recently, there has been active research and development in alternative testing methods, with the European Union leading the way in banning animal testing for cosmetics and the FDA’s Modernization Act 2.0 aiming to allow pharmaceutical development without animal testing. Specifically, our skin organoid model, based on pioneering technology, closely resembles human skin and overcomes both ethical issues in animal testing and technological challenges due to species differences. This gives us a competitive edge. We are currently in discussions with global pharmaceutical companies in the U.S. for the commercialization of animal alternative testing.“
The company is accelerating its skin organoid-based efficacy evaluation services, leveraging this newly registered patent. Kangstem Biotech has already conducted medical device efficacy evaluations using skin organoids in collaboration with LG Electronics and plans to expand its business areas for efficacy evaluation through disease modeling and standardization efforts, including atopic dermatitis and specific diseases. Additionally, the company will sequentially promote the commercialization of efficacy evaluation services for skin-whitening, regeneration, anti-aging, and more.